GENELUX CORP (GNLX) Stock Price, Forecast & Analysis
NASDAQ:GNLX • US36870H1032
GNLX Key Statistics, Chart & Performance
The current stock price of GNLX is 2.56 USD. In the past month the price decreased by -6.57%. In the past year, price decreased by -46.78%.
GNLX Technical Analysis
GNLX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GNLX. While GNLX seems to be doing ok healthwise, there are quite some concerns on its profitability.
GNLX Financial Highlights
Over the last trailing twelve months GNLX reported a non-GAAP Earnings per Share(EPS) of -0.88. The EPS increased by 7.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -127.56% | ||
| ROE | -171.45% | ||
| Debt/Equity | 0 |
GNLX Forecast & Estimates
12 analysts have analysed GNLX and the average price target is 19.72 USD. This implies a price increase of 670.31% is expected in the next year compared to the current price of 2.56.
For the next year, analysts expect an EPS growth of 9.9% and a revenue growth -100% for GNLX
GNLX Ownership
GNLX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.04 | 409.148B | ||
| AMGN | AMGEN INC | 16.57 | 198.801B | ||
| GILD | GILEAD SCIENCES INC | 17.41 | 192.281B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.41 | 124.696B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.08 | 84.911B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.65 | 41.535B | ||
| INSM | INSMED INC | N/A | 31.724B | ||
| BIIB | BIOGEN INC | 12.86 | 28.841B | ||
| NTRA | NATERA INC | N/A | 28.695B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.37 | 20.396B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GNLX
Company Profile
Genelux Corp. manufactures and markets drugs and virus strains solutions. The company is headquartered in Westlake Village, California and currently employs 24 full-time employees. The company went IPO on 2023-01-26. The firm is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
Company Info
GENELUX CORP
2625 Townsgate Road, Suite 230
Westlake Village CALIFORNIA US
Employees: 24
Phone: 18052679889
GENELUX CORP / GNLX FAQ
Can you describe the business of GENELUX CORP?
Genelux Corp. manufactures and markets drugs and virus strains solutions. The company is headquartered in Westlake Village, California and currently employs 24 full-time employees. The company went IPO on 2023-01-26. The firm is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
Can you provide the latest stock price for GENELUX CORP?
The current stock price of GNLX is 2.56 USD. The price decreased by -1.92% in the last trading session.
Does GNLX stock pay dividends?
GNLX does not pay a dividend.
How is the ChartMill rating for GENELUX CORP?
GNLX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the market capitalization of GNLX stock?
GENELUX CORP (GNLX) has a market capitalization of 114.46M USD. This makes GNLX a Micro Cap stock.
What is the Short Interest ratio of GENELUX CORP (GNLX) stock?
The outstanding short interest for GENELUX CORP (GNLX) is 7.92% of its float.